Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P852

ECE2006 Poster Presentations Thyroid (174 abstracts)

Staging of progressive papillary, follicular, or medullary thyroid carcinomas: Comparison of various staging procedures to define the extent and progress of disease

A Matuszczyk 1 , S Petersenn 1 , A Bockisch 2 , S Sheu 3 , P Veit 4 & K Mann 1


1University Duisburg-Essen, Division of Endocrinology, Medical Center, Essen, Germany; 2University Duisburg-Essen, Department of Nuclear Medicine, Essen, Germany; 3University Duisburg-Essen, Department of Pathology, Essen, Germany; 4University Duisburg-Essen, Department of Radiology, Essen, Germany.


Aim: Metastatic medullary (MTC) or iodine-negative papillary (PTC) or follicular (FTC) thyroid carcinomas present a challenge due to limited treatment options. We prospectively compared various staging procedures that may be necessary to define extent and progress of the disease.

Methods: 31 patients were included (9×MTC, 8×PTC, 14×FTC). Staging procedures included CTs of chest, abdomen, and CNS, 18FGD-PET, and bone scan. Tumor spread was defined by evidence of tumor detected in any of the methods. In MTC, tumor distribution included neck (56%), lung (100%), liver (44%), other abdominal organs (22%), CNS (22%), and bone (78%). In PTC and FTC, tumor was detected in neck (50%, 43%), lung (100%, 100%), liver (25%, 0%), other abdominal organs (25%, 7%), CNS (13%, 0%), and bone (50%, 36%), respectively. For comparative evaluation, procedures had to be performed within 2 weeks.

Results: In MTC, CTs localized all tumor masses except bone metastases (71%). PET identified 89%, 60%, 75%, and 43% of the thorax, neck, liver, and bone metastases. The bone scan detected all bone metastases. Disease progress became evident by CTs, PET, and bone scan in 86%, 86%, and 71% of patients, respectively. In PTC and FTC, both CTs and PET identified all metastases except for bone. Bone metastases were detected by CTs, PET, and bone scan in 75%, 75%, and 88% of patients, respectively. Disease progress was seen in PET (100%) and CT (90%). CNS metastases was identified by CCT only.

Conclusion: In MTC, CTs of the chest, abdomen, and CNS, combined with a bone scan are required to determine the full extent of the disease, and may therefore also be used for follow-up. In PTC and FTC, 18FDG-PET correctly identified tumor spread and progress in most patients, with the addition of CT for the CNS. A bone scan provided some additional information.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.